The production of monoclonal antibodies (mAbs) has revolutionized medical treatments across human and veterinary fields, offering precise and effective therapies for a range of conditions. Traditional methods of mAb production involve mammalian cell lines, which, while effective, are costly and complex. Recent advancements in plant biotechnology have introduced a novel and cost-effective alternative: plant-based platforms for mAb production. This article explores the potential of harnessing plant platforms for the production of mAbs in veterinary medicine, detailing the mechanisms, advantages, and challenges associated with this innovative approach. Plant-based systems offer several benefits, including reduced production costs, enhanced safety profiles, and scalability. However, challenges such as regulatory hurdles and plant-specific glycosylation patterns must be addressed to fully realize their potential. This review aims to provide a comprehensive overview of current developments and future prospects in plant-based mAb production, emphasizing its implications for veterinary therapeutics.
HTML PDFShare this article
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
